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A survey done in 1998 and repeated in 2002 and 2008 found the prevalence of peanut and tree nut allergies in adults to be 1.3%. [2] [3] [4] However, the prevalence among children increased from 0.6% in 1997, to 1.2% in 2002 and 2.1% in 2008. Peanut allergy was reported in 0.4% in 1998, 0.8% in 2002, and 1.4% in 2008. 3 It is estimated that 21% of peanut allergy patients may outgrow their allergy. 5 
Current Treatment
There are currently no approved treatments to desensitize patients who are allergic to peanuts. Current management of the allergy is centered on avoidance of peanuts or products that may contain peanuts. This can be a challenge due to cross contact during manufacturing and hidden ingredients. Some nonfood sources such as hair and skin products may also contain peanut protein. Patients with moderate to severe peanut allergies are advised to keep an epinephrine autoinjector for acute systemic reactions. Because 21% of patients may outgrow their allergy, patients are monitored to see whether their tolerance to peanut protein changes. This becomes less likely after age 6.
6 Some physicians will use a desensitization protocol that slowly titrates exposure of peanut protein to increase tolerance. 
New Treatment Options
Two drugs that allow controlled desensitization have reached phase III trials (Table 1) . Both AR101 and Viaskin Peanut have been designated Fast Track and Breakthrough Therapy status by the Food and Drug Administration (FDA).
AR101 is an oral immunotherapy treatment consisting of a standardized preparation of peanut protein. Patients are initiated on a low dose and titrated to a maintenance dose to desensitize them for peanut protein. The initial dose and each dose titration are given under observation in a physician's office in case rescue medication is needed. Doses are given at home between titrations and after the 300 mg maintenance dose is reached. In a 6-month, 55-patient, phase II trial, 79% of patients treated with AR101 tolerated a 443 mg peanut protein challenge compared with 19% in the placebo group. In addition, 62% were able to tolerate 1043 mg of peanut protein. 9 Aimmune Therapeutics announced that in a 554-patient, phase III trial, 67% of patients who received AR101 were able to tolerate a 600 mg dose of peanut protein compared with 4% with placebo and 50% of patients tolerated 1000 mg of peanut protein. 7 The Viaskin peanut allergy transdermal patch is an epicutaneous immunotherapy that delivers peanut protein to the immune system through intact skin. The amount of peanut protein exposure is titrated by adjusting the amount of time the patch is left on. For the first week, the patch is worn for 6 hours. The patient wears the patch for 12 hours in the second 797266H PXXXX10.1177/0018578718797266Hospital PharmacyWalker research-article2018 1 Prescribe Right, LLC, Wildwood, NJ, USA week and leaves the patch on for 24 hours beginning in the third week. Each patch is worn for one day and the site is rotated among 6 sites on the upper back each day. 7 Two phase II trials have been published for the Viaskin peanut patch. Both trials used the amount of peanut protein that could be tolerated before eliciting allergic symptoms as the primary endpoint. In a 12-month, 221-patient, phase II trial, 50% of the patients who received a Viaskin Peanut 250 µg patch tolerated a 1000 mg dose of peanut protein or a 10 times increase from baseline in the amount of peanut protein they could tolerate before the development of clinical symptoms compared with 25% of placebo patients. 10 In a 74-participant, 52-week, phase II trial, 48% of the patients who received a Viaskin Peanut 250 µg patch tolerated a 5044 mg dose of peanut protein or a 10 times increase from baseline in the amount of peanut protein they could tolerate before the development of clinical symptoms compared with 12% of placebo patients.
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Data from 2 unpublished Viaskin peanut patch phase III trial have also been presented. DBV Technologies announced that in a 12-month, 356-patient, phase III, trial, 35% of patients who received a Viaskin peanut patch increased the amount peanut protein they tolerated compared with 13% with placebo. However, the lower boundary of the confidence interval did not reach the prespecified level.
7 DBV Technologies also announced that in a 6-month, 393-patient, phase III safety trial, the most common adverse effect with the patch were local application-site reactions. Serious adverse events were similar to placebo.
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